Logo Image
Opinion|Videos|July 29, 2024

ASCO 2024: Emerging Data on Brenetafusp (IMC-F106C) ImmTAC Bispecific in Melanoma

Key opinion leaders analyze unmet needs and emerging trends in melanoma treatment based on findings presented at ASCO 2024.

Episodes in this series

Video content above is prompted by the following:

  • Discuss the emerging data presented at ASCO 2024 on the phase 1 study of IMC-F106C (brenetafusp), a PRAME x CD3 ImmTAC bispecific protein in post-checkpoint cutaneous melanoma. (Abstract)

1. What was the objective of this study?

2. How was this study designed/what methodology was used?

3. What results were presented?

i. Patient population: N=46

A. Prior therapy: 100% anti-PD1, 88% anti-CTLA4, 25% BRAF/MEK inhibitors

ii. Primary objectives:

A. Safety

B. Selection of recommended dose

iii. Secondary objectives:

A. Efficacy

B. ctDNA response

  • Please provide your key takeaways from this study. How might a PRAME x CD3 bispecific product impact the management of melanoma in the future?

Related Content